STOCK TITAN

[Form 4] LandBridge Company LLC Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

On July 1, 2025, SeaStar Medical Holding Corporation (ICU) Chief Medical Officer Kevin Chung filed a Form 4 disclosing the vesting and conversion of 5,000 restricted stock units (RSUs) into common shares. The transaction was coded “M,” signifying a conversion of derivative equity awards rather than an open-market purchase, and carried a price of $0 per share.

After the transaction, Dr. Chung now directly owns 48,184 ICU shares. This figure incorporates 25,000 shares that were previously reported as unvested RSUs in Table II and have been moved to Table I. The filing also corrects a prior one-share rounding error, and no derivative RSUs remain reportable from this grant.

The RSUs originated from a November 15, 2024 grant of 15,000 units that vest in three equal annual tranches beginning July 1, 2024; the current filing reflects the first installment. Because the shares were received under a pre-arranged compensation plan at no cost, the event does not inject new capital into the company nor constitute an open-market confidence signal. Nevertheless, it modestly increases insider equity alignment and provides transparency regarding executive compensation.

Il 1° luglio 2025, il Chief Medical Officer di SeaStar Medical Holding Corporation (ICU), Kevin Chung, ha presentato un Modulo 4 per comunicare la maturazione e conversione di 5.000 unità azionarie vincolate (RSU) in azioni ordinarie. L'operazione è stata classificata come “M”, indicando una conversione di premi azionari derivati e non un acquisto sul mercato aperto, con un prezzo di $0 per azione.

Dopo questa transazione, il dott. Chung possiede direttamente 48.184 azioni ICU. Tale cifra include 25.000 azioni precedentemente riportate come RSU non maturate nella Tabella II e ora trasferite alla Tabella I. La comunicazione corregge inoltre un precedente errore di arrotondamento di una singola azione e non risultano più RSU derivate da questo premio da segnalare.

Le RSU derivano da un premio concesso il 15 novembre 2024 di 15.000 unità, che maturano in tre tranche annuali uguali a partire dal 1° luglio 2024; la presente comunicazione riguarda la prima tranche. Poiché le azioni sono state ricevute nell'ambito di un piano retributivo predefinito senza alcun costo, l'evento non comporta un nuovo apporto di capitale né rappresenta un segnale di fiducia sul mercato aperto. Tuttavia, aumenta leggermente l'allineamento patrimoniale degli insider e garantisce trasparenza sulla remunerazione dei dirigenti.

El 1 de julio de 2025, el Director Médico de SeaStar Medical Holding Corporation (ICU), Kevin Chung, presentó un Formulario 4 revelando la consolidación y conversión de 5,000 unidades de acciones restringidas (RSU) en acciones comunes. La transacción fue codificada como “M”, lo que indica una conversión de premios de acciones derivadas en lugar de una compra en el mercado abierto, con un precio de $0 por acción.

Tras esta operación, el Dr. Chung posee directamente 48,184 acciones de ICU. Esta cifra incluye 25,000 acciones que previamente se reportaron como RSU no consolidadas en la Tabla II y que ahora se han movido a la Tabla I. La presentación también corrige un error de redondeo de una acción anterior y no quedan RSU derivadas pendientes de reporte de esta concesión.

Las RSU provienen de una concesión del 15 de noviembre de 2024 de 15,000 unidades que se consolidan en tres tramos anuales iguales a partir del 1 de julio de 2024; esta presentación refleja la primera entrega. Dado que las acciones se recibieron bajo un plan de compensación preestablecido sin costo, el evento no aporta nuevo capital a la empresa ni constituye una señal de confianza en el mercado abierto. Sin embargo, incrementa modestamente la alineación patrimonial de los insiders y aporta transparencia sobre la compensación ejecutiva.

2025년 7월 1일, SeaStar Medical Holding Corporation(ICU)의 최고 의료 책임자 케빈 청(Kevin Chung)이 5,000개의 제한 주식 단위(RSU)의 권리 확정 및 보통주 전환을 신고하는 Form 4를 제출했습니다. 이 거래는 파생 주식 보상 전환을 의미하는 “M” 코드로 표시되었으며, 주당 가격은 0달러였습니다.

거래 후 청 박사는 직접 48,184주 ICU 주식을 보유하게 되었습니다. 이 수치는 이전에 표 II에 미확정 RSU로 보고된 25,000주를 포함하며, 이 주식들은 표 I로 이동되었습니다. 이번 신고는 이전의 한 주 반올림 오류도 수정했으며, 이 보상에서 보고해야 할 파생 RSU는 더 이상 남아있지 않습니다.

이 RSU는 2024년 11월 15일에 부여된 15,000단위에서 유래했으며, 2024년 7월 1일부터 3년에 걸쳐 세 번에 나누어 권리가 확정됩니다. 이번 신고는 첫 번째 분할분을 반영합니다. 주식은 사전에 정해진 보상 계획에 따라 무상으로 지급되었기 때문에, 이 사건은 회사에 새로운 자본을 투입하지 않으며 공개 시장에서의 신뢰 신호도 아닙니다. 그럼에도 불구하고 내부자 지분 정렬을 소폭 증가시키고 경영진 보상에 대한 투명성을 제공합니다.

Le 1er juillet 2025, le directeur médical de SeaStar Medical Holding Corporation (ICU), Kevin Chung, a déposé un formulaire 4 révélant la levée des restrictions et la conversion de 5 000 unités d’actions restreintes (RSU) en actions ordinaires. La transaction a été codée « M », signifiant une conversion de récompenses en actions dérivées plutôt qu’un achat sur le marché ouvert, avec un prix de 0 $ par action.

Après la transaction, le Dr Chung détient désormais directement 48 184 actions ICU. Ce chiffre comprend 25 000 actions précédemment déclarées comme RSU non acquises dans le tableau II et qui ont été transférées au tableau I. Le dépôt corrige également une erreur d’arrondi d’une action antérieure, et aucune RSU dérivée n’est plus à déclarer pour cette attribution.

Les RSU proviennent d’une attribution du 15 novembre 2024 de 15 000 unités qui se libèrent en trois tranches annuelles égales à partir du 1er juillet 2024 ; le dépôt actuel reflète la première tranche. Étant donné que les actions ont été reçues dans le cadre d’un plan de rémunération préétabli sans coût, cet événement n’apporte pas de nouveau capital à la société ni ne constitue un signal de confiance sur le marché ouvert. Néanmoins, il augmente modestement l’alignement des intérêts des initiés et assure une transparence sur la rémunération des dirigeants.

Am 1. Juli 2025 reichte der Chief Medical Officer von SeaStar Medical Holding Corporation (ICU), Kevin Chung, ein Formular 4 ein, in dem die Vesting und Umwandlung von 5.000 Restricted Stock Units (RSUs) in Stammaktien offengelegt wurden. Die Transaktion wurde mit „M“ codiert, was eine Umwandlung von derivativen Aktienoptionen anzeigt und keinen Kauf am offenen Markt, mit einem Preis von 0 USD pro Aktie.

Nach der Transaktion besitzt Dr. Chung nun direkt 48.184 ICU-Aktien. Diese Zahl beinhaltet 25.000 Aktien, die zuvor als nicht unverfallbare RSUs in Tabelle II gemeldet wurden und nun in Tabelle I verschoben wurden. Die Meldung korrigiert außerdem einen vorherigen Rundungsfehler von einer Aktie, und es sind keine derivativen RSUs aus diesem Grant mehr zu melden.

Die RSUs stammen von einer Zuteilung am 15. November 2024 über 15.000 Einheiten, die in drei gleichen jährlichen Tranchen ab dem 1. Juli 2024 unverfallbar werden; die aktuelle Meldung betrifft die erste Tranche. Da die Aktien im Rahmen eines vorab vereinbarten Vergütungsplans ohne Kosten erhalten wurden, führt das Ereignis weder zu neuem Kapital für das Unternehmen noch stellt es ein Vertrauenssignal am offenen Markt dar. Dennoch erhöht es leicht die Beteiligung der Insider und sorgt für Transparenz bei der Vergütung der Führungskräfte.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; minimal direct market impact.

The filing simply records the first tranche of a previously granted RSU award. Although it boosts Chung’s direct stake to 48,184 shares, the stock was acquired at no cost and does not represent an open-market buy. From a valuation standpoint, the transaction is neutral: it neither alters SeaStar Medical’s cash position nor signals management’s view on current pricing. Investors may view the increased ownership as incremental alignment, but the absolute share count is unlikely to sway the investment thesis given the company’s overall float.

TL;DR: Proper Section 16 reporting; alignment incrementally improved.

The Form 4 is timely and complete, demonstrating compliance with Section 16(a) obligations. Moving previously unvested RSUs into Table I clarifies ownership and enhances disclosure accuracy. While the vesting is standard under the firm’s 2024 equity plan, the absence of remaining derivative units for this grant indicates transparent bookkeeping. Governance watchers may note the small but positive shift in insider-shareholder alignment.

Il 1° luglio 2025, il Chief Medical Officer di SeaStar Medical Holding Corporation (ICU), Kevin Chung, ha presentato un Modulo 4 per comunicare la maturazione e conversione di 5.000 unità azionarie vincolate (RSU) in azioni ordinarie. L'operazione è stata classificata come “M”, indicando una conversione di premi azionari derivati e non un acquisto sul mercato aperto, con un prezzo di $0 per azione.

Dopo questa transazione, il dott. Chung possiede direttamente 48.184 azioni ICU. Tale cifra include 25.000 azioni precedentemente riportate come RSU non maturate nella Tabella II e ora trasferite alla Tabella I. La comunicazione corregge inoltre un precedente errore di arrotondamento di una singola azione e non risultano più RSU derivate da questo premio da segnalare.

Le RSU derivano da un premio concesso il 15 novembre 2024 di 15.000 unità, che maturano in tre tranche annuali uguali a partire dal 1° luglio 2024; la presente comunicazione riguarda la prima tranche. Poiché le azioni sono state ricevute nell'ambito di un piano retributivo predefinito senza alcun costo, l'evento non comporta un nuovo apporto di capitale né rappresenta un segnale di fiducia sul mercato aperto. Tuttavia, aumenta leggermente l'allineamento patrimoniale degli insider e garantisce trasparenza sulla remunerazione dei dirigenti.

El 1 de julio de 2025, el Director Médico de SeaStar Medical Holding Corporation (ICU), Kevin Chung, presentó un Formulario 4 revelando la consolidación y conversión de 5,000 unidades de acciones restringidas (RSU) en acciones comunes. La transacción fue codificada como “M”, lo que indica una conversión de premios de acciones derivadas en lugar de una compra en el mercado abierto, con un precio de $0 por acción.

Tras esta operación, el Dr. Chung posee directamente 48,184 acciones de ICU. Esta cifra incluye 25,000 acciones que previamente se reportaron como RSU no consolidadas en la Tabla II y que ahora se han movido a la Tabla I. La presentación también corrige un error de redondeo de una acción anterior y no quedan RSU derivadas pendientes de reporte de esta concesión.

Las RSU provienen de una concesión del 15 de noviembre de 2024 de 15,000 unidades que se consolidan en tres tramos anuales iguales a partir del 1 de julio de 2024; esta presentación refleja la primera entrega. Dado que las acciones se recibieron bajo un plan de compensación preestablecido sin costo, el evento no aporta nuevo capital a la empresa ni constituye una señal de confianza en el mercado abierto. Sin embargo, incrementa modestamente la alineación patrimonial de los insiders y aporta transparencia sobre la compensación ejecutiva.

2025년 7월 1일, SeaStar Medical Holding Corporation(ICU)의 최고 의료 책임자 케빈 청(Kevin Chung)이 5,000개의 제한 주식 단위(RSU)의 권리 확정 및 보통주 전환을 신고하는 Form 4를 제출했습니다. 이 거래는 파생 주식 보상 전환을 의미하는 “M” 코드로 표시되었으며, 주당 가격은 0달러였습니다.

거래 후 청 박사는 직접 48,184주 ICU 주식을 보유하게 되었습니다. 이 수치는 이전에 표 II에 미확정 RSU로 보고된 25,000주를 포함하며, 이 주식들은 표 I로 이동되었습니다. 이번 신고는 이전의 한 주 반올림 오류도 수정했으며, 이 보상에서 보고해야 할 파생 RSU는 더 이상 남아있지 않습니다.

이 RSU는 2024년 11월 15일에 부여된 15,000단위에서 유래했으며, 2024년 7월 1일부터 3년에 걸쳐 세 번에 나누어 권리가 확정됩니다. 이번 신고는 첫 번째 분할분을 반영합니다. 주식은 사전에 정해진 보상 계획에 따라 무상으로 지급되었기 때문에, 이 사건은 회사에 새로운 자본을 투입하지 않으며 공개 시장에서의 신뢰 신호도 아닙니다. 그럼에도 불구하고 내부자 지분 정렬을 소폭 증가시키고 경영진 보상에 대한 투명성을 제공합니다.

Le 1er juillet 2025, le directeur médical de SeaStar Medical Holding Corporation (ICU), Kevin Chung, a déposé un formulaire 4 révélant la levée des restrictions et la conversion de 5 000 unités d’actions restreintes (RSU) en actions ordinaires. La transaction a été codée « M », signifiant une conversion de récompenses en actions dérivées plutôt qu’un achat sur le marché ouvert, avec un prix de 0 $ par action.

Après la transaction, le Dr Chung détient désormais directement 48 184 actions ICU. Ce chiffre comprend 25 000 actions précédemment déclarées comme RSU non acquises dans le tableau II et qui ont été transférées au tableau I. Le dépôt corrige également une erreur d’arrondi d’une action antérieure, et aucune RSU dérivée n’est plus à déclarer pour cette attribution.

Les RSU proviennent d’une attribution du 15 novembre 2024 de 15 000 unités qui se libèrent en trois tranches annuelles égales à partir du 1er juillet 2024 ; le dépôt actuel reflète la première tranche. Étant donné que les actions ont été reçues dans le cadre d’un plan de rémunération préétabli sans coût, cet événement n’apporte pas de nouveau capital à la société ni ne constitue un signal de confiance sur le marché ouvert. Néanmoins, il augmente modestement l’alignement des intérêts des initiés et assure une transparence sur la rémunération des dirigeants.

Am 1. Juli 2025 reichte der Chief Medical Officer von SeaStar Medical Holding Corporation (ICU), Kevin Chung, ein Formular 4 ein, in dem die Vesting und Umwandlung von 5.000 Restricted Stock Units (RSUs) in Stammaktien offengelegt wurden. Die Transaktion wurde mit „M“ codiert, was eine Umwandlung von derivativen Aktienoptionen anzeigt und keinen Kauf am offenen Markt, mit einem Preis von 0 USD pro Aktie.

Nach der Transaktion besitzt Dr. Chung nun direkt 48.184 ICU-Aktien. Diese Zahl beinhaltet 25.000 Aktien, die zuvor als nicht unverfallbare RSUs in Tabelle II gemeldet wurden und nun in Tabelle I verschoben wurden. Die Meldung korrigiert außerdem einen vorherigen Rundungsfehler von einer Aktie, und es sind keine derivativen RSUs aus diesem Grant mehr zu melden.

Die RSUs stammen von einer Zuteilung am 15. November 2024 über 15.000 Einheiten, die in drei gleichen jährlichen Tranchen ab dem 1. Juli 2024 unverfallbar werden; die aktuelle Meldung betrifft die erste Tranche. Da die Aktien im Rahmen eines vorab vereinbarten Vergütungsplans ohne Kosten erhalten wurden, führt das Ereignis weder zu neuem Kapital für das Unternehmen noch stellt es ein Vertrauenssignal am offenen Markt dar. Dennoch erhöht es leicht die Beteiligung der Insider und sorgt für Transparenz bei der Vergütung der Führungskräfte.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bolling Harrison Fenner

(Last) (First) (Middle)
5555 SAN FELIPE STREET, SUITE 1200

(Street)
HOUSTON TX 77056

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LandBridge Co LLC [ LB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A shares 07/01/2025 F 8,366(1) D $66.38 66,024 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. In connection with the vesting and settlement of restricted share units ("RSUs") through the issuance of Class A shares of LandBridge Company LLC (the "Issuer") pursuant to the LandBridge Company LLC Long-Term Incentive Plan, the Issuer withheld Class A shares that would otherwise have been issued to the Reporting Person to satisfy their tax withholding obligations.
Remarks:
Executive Vice President and General Counsel
/s/ Scott L. McNeely, Attorney-In-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Landbridge Company Llc

NYSE:LB

LB Rankings

LB Latest News

LB Latest SEC Filings

LB Stock Data

1.57B
22.60M
2.82%
84.95%
15.88%
Oil & Gas Equipment & Services
Oil Royalty Traders
Link
United States
HOUSTON